CAMBRIDGE, Mass., Aug. 3, 2022
/PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX)
(Theseus or the Company), a clinical-stage biopharmaceutical
company focused on improving the lives of cancer patients through
the discovery, development and commercialization of
transformative targeted therapies, today announced
that it will participate virtually in the 2022 Wedbush PacGrow
Healthcare Conference, taking place August
9-10, 2022.
Presentation Details:
Event: Wedbush PacGrow Healthcare Conference
Date / Time: Wednesday, August
10th, 2022, at 10:20am
ET
Format: Panel Discussion
A live webcast will be available in the Events section of the
company's investor relations website
at ir.theseusrx.com and archived for 30 days following
the presentation.
Management will also be participating in one-on-one investor
meetings throughout the conference. Investors interested in
scheduling a meeting with the Theseus management team should
contact their Wedbush representative.
About Theseus Pharmaceuticals,
Inc.
Theseus is a clinical-stage biopharmaceutical company focused on
improving the lives of cancer patients through the discovery,
development and commercialization of transformative targeted
therapies. Theseus is working to outsmart cancer resistance by
developing pan-variant tyrosine kinase inhibitors (TKIs) to target
all known classes of cancer-causing and resistance mutations that
lead to variants in a particular protein in a given type of cancer.
Theseus' lead product candidate, THE-630, is a pan-variant KIT
inhibitor for the treatment of patients with advanced
gastrointestinal stromal tumors (GIST), whose cancer has developed
resistance to earlier lines of kinase inhibitor therapy. Theseus is
also developing a fourth-generation, selective epidermal growth
factor receptor (EGFR) inhibitor for C797S-mediated resistance to
first- or later-line osimertinib treatment in patients with
non-small cell lung cancer (NSCLC). For more information,
visit www.theseusrx.com.
Media Contact
Amy Jobe,
Ph.D.
LifeSci Communications
315-879-8192
ajobe@lifescicomms.com
Investor Contact
Christen
Baglaneas
Theseus Pharmaceuticals
857-706-4993
christen.baglaneas@theseusrx.com
Josh Rappaport
Stern Investor Relations
212-362-1200
josh.rappaport@sternir.com
View original
content:https://www.prnewswire.com/news-releases/theseus-pharmaceuticals-to-participate-virtually-in-wedbush-pacgrow-healthcare-conference-301598489.html
SOURCE Theseus Pharmaceuticals